Table 1.
Baseline clinical and procedural characteristics of all patients with and without CI-AKI.
| Variable | Total (n = 3848) |
CIAKI (n = 651) |
Non-CIAKI (n = 3197) |
p value |
|---|---|---|---|---|
| Age (years) | 66.6 ± 10.7 | 68.7 ± 10.8 | 66.1 ± 10.6 | < 0.001 |
| Female, N (%) | 1306(33.9%) | 259(39.8%) | 1047(32.7%) | < 0.001 |
| BMI (kg/m2) | 22.12 ± 8.7 | 22.87 ± 8.33 | 21.98 ± 8.77 | 0.015 |
| Hypertension, N (%) | 2360(61.3%) | 401(61.6%) | 1959(61.3%) | 0.878 |
| Diabetes, N (%) | 859(22.3%) | 163(25%) | 696(21.8%) | 0.068 |
| HF, N (%) | 1852(48.1%) | 361(55.5%) | 1491(46.6%) | < 0.001 |
| Smoking, N (%) | 676(17.6%) | 102(15.7%) | 574(18%) | 0.162 |
| Drinking, N (%) | 618(16.1%) | 90(13.8%) | 528(16.5%) | 0.088 |
| CRP (mg/L) | 9.56 ± 21.20 | 14.39 ± 27.61 | 8.58 ± 19.50 | < 0.001 |
| NLR | 3.68 ± 4.46 | 5.11 ± 7.54 | 3.38 ± 3.44 | < 0.001 |
| Hemoglobin (g/dL) | 12.87 ± 1.86 | 12.30 ± 2.12 | 13.02 ± 1.75 | < 0.001 |
| EF(%) | 60.22 ± 12.85 | 56.95 ± 13.33 | 60.89 ± 12.65 | < 0.001 |
| NT-proBNP, pg/mL | 1378.65 ± 2177.76 | 2357.52 ± 3098.51 | 1172.17 ± 1864.46 | < 0.001 |
| eGFR, mL/min/1.73m2 | 83.99 ± 16.82 | 84.78 ± 19.27 | 83.83 ± 16.28 | 0.253 |
| Excess volumes of CM, N (%) | 67(1.9%) | 11(1.8%) | 56(1.9%) | 0.865 |
| Iso-osmolar CM, N (%) | 1063(27.7%) | 169(26.0%) | 894(28.1%) | 0.287 |
| Diuretics, N (%) | 1199(31.2%) | 211(32.4%) | 988(30.9%) | 0.449 |
| RAS inhibitors, N (%) | 1691(43.9%) | 256(39.3%) | 1435(44.9%) | 0.009 |
Data are presented as mean ± SD, absolute n (%), or median (inter quartile range). The p values for continuous data were obtained from the analysis of the non-parametric Mann–Whitney U test, the p values for categorical data were obtained from the chi-square test. CI-AKI contrast-induced acute kidney injury; BMI body mass index; HF heart failure; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; TC total cholesterol; LDL-C low-density lipoprotein cholesterol; EF ejection fraction; NT-proBNP N-terminal pro b-type natriuretic peptide; eGFR estimated glomerular filtration rate; CM contrast medium; RAS renin-angiotensin system.